Find uplifting stories about heroes, innovations, and solutions
18 results for "ibogaine"
A single treatment with ibogaine, a powerful plant-based compound, helped 30 special forces veterans significantly reduce their PTSD symptoms in a Stanford University study. The promising results offer new hope for military veterans struggling with trauma and mental health challenges.
President Trump signed an executive order directing the FDA to expedite review of psychedelic drugs showing promise for veterans suffering from PTSD, depression, and traumatic brain injuries. One treatment already shows an 80-90% reduction in symptoms within one month.
A presidential order is accelerating research on ibogaine, a plant-based treatment showing promise for veterans with PTSD and people battling depression. The FDA says approval could come within months instead of years.
A groundbreaking trial shows military veterans experiencing dramatic improvements in PTSD symptoms after just one session with ibogaine, a powerful natural psychedelic. The research could open new doors for millions struggling with treatment-resistant trauma.
President Trump will sign an executive order Saturday to advance research into psychedelics like psilocybin and ibogaine for therapeutic use. The move could open doors for controlled access to these promising mental health treatments.
A new executive order cuts red tape for scientists studying psychedelic compounds like MDMA and psilocybin as treatments for depression, PTSD, and addiction. The breakthrough also includes $50 million for research into ibogaine, a powerful substance showing promise for opioid addiction.
President Trump signed an executive order to speed FDA review of psychedelic treatments showing 80-90% reduction in PTSD symptoms among veterans. The breakthrough therapy could help over 6,000 veterans who die by suicide each year.
President Trump signed an executive order to accelerate research into psychedelic drugs for mental health treatment, directing $50 million to state programs. Veterans and advocacy groups hope the move could unlock new treatments for PTSD and depression.
President Trump signed an executive order to expand access to psychedelic therapies for conditions like PTSD, depression, and addiction. The move signals growing mainstream acceptance of treatments once considered fringe medicine.
A sweeping executive order is accelerating psychedelic research for mental health treatment, unlocking funding and pathways that researchers have sought for years. The question now: Can scientists deliver on the promise fast enough to help those in crisis?
President Trump signed an executive order to speed up research and potential FDA approval of psychedelic therapies for veterans suffering from PTSD, depression, and addiction. While the move brings hope to those who've exhausted traditional treatments, experts emphasize these therapies still need rigorous testing in controlled settings.
The FDA is accelerating breakthrough psychedelic therapies for treatment-resistant depression, PTSD, and alcohol use disorder after a presidential directive. Veterans and millions struggling with serious mental illness could gain access to promising new options backed by rigorous science.
A new executive order accelerates research into psychedelic medicines for mental illness, prioritizing veterans facing treatment-resistant PTSD and depression. The move ends decades of federal prohibition and could offer hope to the 17 veterans who die by suicide every day.
President Trump signed an executive order directing federal agencies to speed up approval of psychedelic therapies for PTSD, backed by $50 million in new research funding. The move could bring relief to millions of veterans and trauma survivors as soon as this summer.
The Justice Department moved state-licensed medical marijuana from Schedule I to Schedule III, opening doors for research and expanded treatment options. Veterans and patients with mental health conditions could benefit most from the policy shift.
The FDA is accelerating approval for psilocybin and MDMA-like therapies to treat depression and PTSD, potentially opening new doors for millions struggling with mental health conditions. Three companies are now on an expedited path to bring these promising treatments to patients who haven't found relief from traditional options.
America's veterans are getting access to breakthrough mental health treatments faster thanks to a historic partnership between two federal agencies. The collaboration aims to turn promising research into real care for those struggling with serious mental illness.
A Madison nonprofit just became one of three organizations nationwide chosen to speed breakthrough mental health treatments to patients faster. The federal government is slashing review times from up to 10 months down to just one or two.